VIP (Vasoactive Intestinal Peptide): Mechanisms, Research, and 2026 Findings

• VIP is a naturally occurring 28-amino acid neuropeptide with a blood half-life of roughly two minutes, produced in the gut, pancreas, and brain.
• It acts across multiple body systems simultaneously — digestive, cardiovascular, immune, and circadian — making it one of the more broadly acting neuropeptides studied today.
• A May 2026 study found that VIP triggers mitochondrial fragmentation in nasopharyngeal carcinoma cells via the PKCδ-Drp1 axis, opening a new line of oncology inquiry.
• Intranasal and subcutaneous routes are the two administration methods most studied in research settings, with doses ranging widely based on the target system.

What Is VIP?

Vasoactive intestinal peptide — commonly abbreviated VIP — is a 28-amino acid peptide hormone and neuropeptide. It belongs to the glucagon/secretin superfamily and binds to class II G protein-coupled receptors. In humans, it is encoded by the VIP gene.

VIP was first identified in 1970. Since then, researchers have found it is produced in many tissues throughout the body, including the gut, the pancreas, the neocortex, and the suprachiasmatic nuclei of the hypothalamus — the brain's central clock. This wide distribution is a key reason why VIP influences so many different systems.

When VIP enters the bloodstream, it has a half-life of about two minutes. It is cleared quickly, which means its effects are rapid and localized rather than long-lasting systemically. This short half-life also has practical implications for research dosing and timing, since the peptide does not accumulate in the blood under normal conditions.

VIP acts as both a neurotransmitter and a hormone depending on where it is released. Its two primary receptors — VPAC1 and VPAC2 — are found on cells throughout the gut, lungs, immune system, and brain.

What VIP Does in the Gut and Cardiovascular System

The gut is where VIP's physiological role is most studied. In the digestive tract, VIP relaxes smooth muscle in the lower esophageal sphincter, the stomach, and the gallbladder. At the same time, it stimulates the secretion of water and electrolytes into the intestinal lumen, which increases motility — the movement of food and waste through the digestive tract.

VIP also inhibits gastric acid secretion and stimulates water secretion into pancreatic juice and bile. It triggers pepsinogen release from chief cells in the stomach lining. Together, these actions suggest that VIP plays a regulatory and protective role in normal digestion.

Research has also noted that VIP is relevant in inflammatory bowel diseases. Mast cell signaling and VIP activity are both upregulated in conditions like Crohn's disease. Whether VIP is driving inflammation, responding to it, or attempting to limit it remains an active area of investigation.

In the cardiovascular system, VIP produces coronary vasodilation — it widens the blood vessels of the heart — and lowers arterial blood pressure. It also has a positive inotropic effect, meaning it increases the force of heart contractions, and a positive chronotropic effect, meaning it increases heart rate. It relaxes smooth muscle in the trachea as well. These cardiovascular actions are consistent with VIP's broader role as a vasodilatory signaling molecule.

VIP and the Immune System

VIP has well-documented effects on immune regulation. A 2009 study by Smalley, Barrow, and Foster, published in Clinical and Experimental Immunology, examined how VIP modulates innate immune responses. Their work showed that VIP can suppress pro-inflammatory cytokine production and shift immune activity toward anti-inflammatory and regulatory pathways. The authors identified this as a potential avenue for treating inflammatory diseases.

VIP achieves these immune effects largely through its VPAC1 and VPAC2 receptors, both of which are expressed on immune cells. When VIP binds to these receptors, it can reduce the intensity of the inflammatory response — not by suppressing immunity entirely, but by modulating its balance.

A 2026 review article in Nature Reviews Neuroscience by Ehlers and Guerrero-Fonseca looked specifically at how sensory neurons regulate lung immunity — what researchers call neuroimmune control. VIP, as a neuropeptide released by sensory neurons, is part of this signaling system. The review highlights that neuropeptides communicating between the nervous and immune systems in lung tissue are increasingly recognized as important modulators of respiratory immune function. This represents a relatively new lens through which VIP's role in conditions involving lung inflammation is being studied.

Researchers interested in immune-related peptide research may also find it useful to compare VIP's immune-modulating mechanisms with those of BPC-157, which has a separate but also broadly anti-inflammatory profile studied in gut and tissue contexts.

Metabolic and Hormonal Roles

VIP influences appetite, body composition, and metabolic hormone levels. A 2015 study by Vu and colleagues, published in the Journal of Molecular Neuroscience, examined VIP's role in regulating these parameters. The study found that VIP signaling interacts directly with hormones involved in energy balance. Specifically, the researchers demonstrated that VIP affects body composition and metabolic hormone profiles, though the exact mechanisms require further study to fully characterize.

The VPAC2 receptor has drawn particular attention in metabolic research. A 2022 study by Hou and colleagues, published in Frontiers in Endocrinology, reviewed VPAC2's therapeutic potential in type 2 diabetes. The authors described how VIP signaling through VPAC2 affects insulin secretion and glucose regulation — findings that position VIP as a potentially relevant target in metabolic disease research, though no VIP-based therapies have been approved for diabetes.

The fact that VIP is produced in the suprachiasmatic nuclei — the hypothalamic structure that drives circadian rhythms — is also relevant here. Metabolic processes are tightly regulated by the circadian clock, and VIP appears to be part of the signaling that synchronizes time-of-day cues across the body's systems.

For comparison, researchers studying metabolic peptides sometimes look at incretin-class compounds like Semaglutide or Tirzepatide, which also involve gut-brain hormonal axes but through distinct receptor targets and mechanisms.

2026 Oncology Research: VIP and Mitochondrial Fragmentation

A May 2026 paper in Drug Development Research by Xu and Wu reported an unexpected finding about VIP in cancer biology. The study focused on nasopharyngeal carcinoma — a type of cancer originating in the nasopharynx, at the back of the nasal cavity. The researchers found that VIP activated a molecular axis called PKCδ-Drp1 in these cancer cells.

Activation of the PKCδ-Drp1 pathway led to mitochondrial fragmentation — the physical breaking apart of mitochondria within the cancer cells — and caused what the researchers described as a metabolic crisis in those cells. In other words, VIP appeared to disrupt the energy-producing machinery of the carcinoma cells.

This is preclinical research. It does not mean that VIP treats or cures any form of cancer, and the findings have not been validated in human clinical trials. However, the study introduces a new dimension to VIP research: it may interact with cancer cell metabolism in ways that are worth studying further. It also raises the question of whether VIP's metabolic effects differ meaningfully between healthy and malignant cells — a distinction that will need to be explored carefully in future work.

Intranasal VIP and Brain Volume in CIRS

One clinical application of VIP that has received attention in research literature is intranasal delivery in patients with Chronic Inflammatory Response Syndrome, or CIRS. CIRS is an inflammatory condition often associated with biotoxin exposure, including exposure to water-damaged buildings and mold.

A 2017 study by Shoemaker and colleagues, published in Internal Medicine Review, found that intranasal VIP safely restored volume to multiple grey matter nuclei in CIRS patients. The study used neuroimaging to track structural brain changes — specifically, volume in discrete grey matter regions — not just self-reported symptoms. The researchers reported that grey matter volume improved following intranasal VIP administration.

This study is notable for using an objective structural outcome measure. That said, it is a single study in a specific patient population with a condition that is itself still debated in mainstream medicine. The findings should not be extrapolated to other conditions or taken as established clinical guidance.

Research Dosing and Administration Routes

In research settings, VIP is studied via two primary routes. Intranasal doses reported in the literature range from 25 to 200 mcg. Subcutaneous doses typically range from 50 to 300 mcg. Most protocols use one to three administrations per day, depending on the system being studied and the research goal.

The intranasal route is particularly relevant when the research target involves brain tissue or mucosal immunity, since intranasal delivery allows compounds to bypass some of the rapid systemic clearance that VIP faces in the bloodstream. Given VIP's roughly two-minute blood half-life, route of administration matters significantly for what effects are actually observed.

VIP is not an approved pharmaceutical for the indications most commonly studied in research contexts. None of the dosing parameters described here should be interpreted as clinical recommendations. Individual response to VIP varies, and research protocols are designed around carefully controlled conditions that do not translate directly to self-administration.

FAQ

What does vasoactive intestinal peptide actually do?

VIP acts across many systems. In the gut, it relaxes smooth muscle and increases secretion of water and electrolytes. In the cardiovascular system, it dilates blood vessels and lowers blood pressure. In the immune system, it modulates inflammation. In the brain, it plays a role in circadian signaling. Its 28-amino acid structure allows it to bind to VPAC1 and VPAC2 receptors on cells throughout the body.

Why does VIP have such a short half-life?

VIP has a blood half-life of roughly two minutes. This is common among neuropeptides that function as local signals. Short half-lives prevent the signal from spreading too widely or persisting too long, which gives the body precise control over when and where VIP acts. This also means that intranasal or direct tissue delivery may be more effective than intravenous routes for research applications targeting specific tissues.

What is the PKCδ-Drp1 finding in the 2026 cancer study?

A May 2026 study in Drug Development Research found that in nasopharyngeal carcinoma cells, VIP activated a signaling pathway called PKCδ-Drp1. This caused the mitochondria in those cancer cells to fragment and triggered what the researchers called a metabolic crisis. This is an early preclinical finding and does not indicate that VIP is a cancer treatment. It does suggest that VIP may interact with cancer cell metabolism in ways researchers will want to study further.

What is the connection between VIP and CIRS or mold illness?

A 2017 study by Shoemaker and colleagues found that intranasal VIP restored volume to multiple grey matter nuclei in patients diagnosed with Chronic Inflammatory Response Syndrome (CIRS), a condition linked to biotoxin exposure including mold. This is a single study in a specific and narrowly defined patient group. It does not mean VIP reverses brain damage broadly, and it should not be used as the basis for self-treatment decisions.

How does VIP differ from other peptides studied for inflammation?

VIP is a neuropeptide — it originates in and acts on the nervous system as well as the immune system. Its anti-inflammatory effects work through VPAC receptors on immune cells and by reducing pro-inflammatory cytokine production. Peptides like BPC-157 or TB-500 act via different mechanisms and receptor targets. VIP's circadian and metabolic dimensions also set it apart from peptides focused primarily on tissue repair or localized injury response.